Candel Therapeutics (NASDAQ:CADL) Raised to Hold at Zacks Research

Candel Therapeutics (NASDAQ:CADL) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other analysts also recently weighed in on CADL. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Wednesday, January 21st. Stephens reissued an “overweight” rating and set a $15.00 price target on shares of Candel Therapeutics in a research note on Monday, December 8th. Citigroup lowered their price objective on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Friday, November 14th. Finally, Wall Street Zen cut shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.00.

Candel Therapeutics Price Performance

CADL opened at $5.11 on Monday. The stock has a 50-day moving average price of $5.63 and a 200-day moving average price of $5.44. Candel Therapeutics has a 12-month low of $4.25 and a 12-month high of $9.08. The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $280.54 million, a P/E ratio of -8.96 and a beta of -0.91.

Insider Transactions at Candel Therapeutics

In related news, Director Paul B. Manning purchased 550,458 shares of Candel Therapeutics stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average cost of $5.45 per share, for a total transaction of $2,999,996.10. Following the transaction, the director directly owned 2,763,527 shares in the company, valued at $15,061,222.15. The trade was a 24.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 16.60% of the stock is currently owned by insiders.

Institutional Trading of Candel Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Financial Markets grew its holdings in shares of Candel Therapeutics by 128.2% in the third quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock worth $40,000 after purchasing an additional 4,439 shares during the last quarter. Tower Research Capital LLC TRC boosted its position in Candel Therapeutics by 361.7% during the 2nd quarter. Tower Research Capital LLC TRC now owns 9,608 shares of the company’s stock valued at $49,000 after buying an additional 7,527 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Candel Therapeutics during the 4th quarter valued at $51,000. Invesco Ltd. bought a new stake in Candel Therapeutics in the 1st quarter worth $59,000. Finally, ProShare Advisors LLC purchased a new position in shares of Candel Therapeutics in the fourth quarter valued at about $59,000. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Company Profile

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.